AIM-Harvard/TrialPanorama-filtered huggingface dataset:
Study 34016799 — intervention group
Group type: EXPERIMENTAL
Intervention: STrIP score
Number of subjects: 0
Study 34016799 — intervention group
Group type: COMPARATOR
Intervention: Transcutaneous bilirubinometer
Number of subjects: 0
Study 34016799 — intervention group
Group type: COMPARATOR
Intervention: Kramer scale
Number of subjects: 0
Study 33632110 — intervention group
Group type: EXPERIMENTAL
Intervention: Immediate-release oxycodone 30 mg
Number of subjects: 12
Study 33632110 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 12
Study 34395716 — intervention group
Group type: EXPERIMENTAL
Intervention: Piperacillin-tazobactam 4.5 g every 6 hours
Number of subjects: 72
Study 34395716 — intervention group
Group type: COMPARATOR
Intervention: Meropenem 1 g every 8 hours
Number of subjects: 72
Study 33123968 — intervention group
Group type: EXPERIMENTAL
Intervention: Trilaciclib 240 mg/m2
Number of subjects: 61
Study 33123968 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 61
Study 32394350 — intervention group
Group type: EXPERIMENTAL
Intervention: TP (docetaxel: 75 mg/m2 or paclitaxel 175 mg/m2 d1; carboplatin AUC=5, day 1)
Number of subjects: 308
Study 32394350 — intervention group
Group type: COMPARATOR
Intervention: EC (epirubicin: 90 mg/m2; cyclophosphamide: 600 mg/m2, day 1) followed by T (docetaxel: 75 mg/m2 or paclitaxel 175 mg/m2, day 1)
Number of subjects: 308
Study 33905798 — intervention group
Group type: EXPERIMENTAL
Intervention: APRV
Number of subjects: 65
Study 33905798 — intervention group
Group type: COMPARATOR
Intervention: P-SIMV+PS
Number of subjects: 65
Study 33731255 — intervention group
Group type: EXPERIMENTAL
Intervention: Conditional cash transfer ($20 per visit)
Number of subjects: 100
Study 33731255 — intervention group
Group type: EXPERIMENTAL
Intervention: Conditional cash transfer ($40 per visit)
Number of subjects: 100
Study 33731255 — intervention group
Group type: COMPARATOR
Intervention: Control group (no cash incentive)
Number of subjects: 100
Study 36374435 — intervention group
Group type: EXPERIMENTAL
Intervention: HLaC Online intervention (online nutrition, physical activity, and psychosocial support)
Number of subjects: 27
Study 36374435 — intervention group
Group type: EXPERIMENTAL
Intervention: HLaC Online intervention (with recommended changes such as simple activities and guidance videos)
Number of subjects: 27
Study 36374435 — intervention group
Group type: EXPERIMENTAL
Intervention: HLaC Online intervention
Number of subjects: 27
Study 33450473 — intervention group
Group type: EXPERIMENTAL
Intervention: CPR video
Number of subjects: 27
Study 33450473 — intervention group
Group type: COMPARATOR
Intervention: No video
Number of subjects: 27
Study 32223479 — intervention group
Group type: EXPERIMENTAL
Intervention: Walking for 30 minutes, 3 times a week at 4 km/h
Number of subjects: 60
Study 32223479 — intervention group
Group type: COMPARATOR
Intervention: Usual work and household activities (Control)
Number of subjects: 60
Study 34692842 — intervention group
Group type: EXPERIMENTAL
Intervention: Lymphocyte active immunotherapy
Number of subjects: 124
Study 34692842 — intervention group
Group type: COMPARATOR
Intervention: Conventional treatment
Number of subjects: 124
Study 35722862 — intervention group
Group type: EXPERIMENTAL
Intervention: Naltrexone
Number of subjects: 118
Study 33310789 — intervention group
Group type: EXPERIMENTAL
Intervention: eCBTI via a Smartphone application
Number of subjects: 200
Study 33310789 — intervention group
Group type: COMPARATOR
Intervention: TAU
Number of subjects: 200
Study 36410041 — intervention group
Group type: EXPERIMENTAL
Intervention: Clopidogrel plus aspirin
Number of subjects: 6662
Study 36410041 — intervention group
Group type: COMPARATOR
Intervention: Ticagrelor plus aspirin
Number of subjects: 6662
Study 34886145 — intervention group
Group type: EXPERIMENTAL
Intervention: FFP2/N95 mask
Number of subjects: 50
Study 34886145 — intervention group
Group type: EXPERIMENTAL
Intervention: Surgical mask
Number of subjects: 50
Study 34886145 — intervention group
Group type: EXPERIMENTAL
Intervention: No mask
Number of subjects: 50
Study 32555559 — intervention group
Group type: EXPERIMENTAL
Intervention: Patients' social and healthcare networks support
Number of subjects: 8
Study 33562743 — intervention group
Group type: EXPERIMENTAL
Intervention: Isometric abdominal training and gluteus medius-specific training (experimental group)
Number of subjects: 25
Study 33562743 — intervention group
Group type: COMPARATOR
Intervention: Isometric abdominal training (control group)
Number of subjects: 25
Study 32143552 — intervention group
Group type: EXPERIMENTAL
Intervention: Moses mode
Number of subjects: 72
Study 32143552 — intervention group
Group type: COMPARATOR
Intervention: Regular mode
Number of subjects: 72
Study 33964964 — intervention group
Group type: EXPERIMENTAL
Intervention: Researcher time for recruitment and baseline data collection
Number of subjects: 0
Study 33964964 — intervention group
Group type: EXPERIMENTAL
Intervention: Recruitment planning and resource allocation
Number of subjects: 0
Study 32311961 — intervention group
Group type: EXPERIMENTAL
Intervention: Curcuminoid complex 500 mg with diclofenac 50 mg
Number of subjects: 140
Study 32311961 — intervention group
Group type: COMPARATOR
Intervention: Diclofenac 50 mg alone
Number of subjects: 140
Study 35031148 — intervention group
Group type: EXPERIMENTAL
Intervention: High-dose quadrivalent influenza vaccine (Fluzone High-Dose Quadrivalent; QIV-HD)
Number of subjects: 2122
Study 33475271 — intervention group
Group type: EXPERIMENTAL
Intervention: Ranibizumab monotherapy
Number of subjects: 322
Study 33475271 — intervention group
Group type: EXPERIMENTAL
Intervention: Combination therapy (Ranibizumab with Verteporfin)
Number of subjects: 322
Study 33475271 — intervention group
Group type: COMPARATOR
Intervention: Not applicable
Number of subjects: 322
Study 32948224 — intervention group
Group type: EXPERIMENTAL
Intervention: Egg white hydrolyzate (5 g/day)
Number of subjects: 93
Study 32948224 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 93
Study 33866020 — intervention group
Group type: EXPERIMENTAL
Intervention: Active rTMS stimulation
Number of subjects: 49
Study 33866020 — intervention group
Group type: COMPARATOR
Intervention: Sham rTMS stimulation
Number of subjects: 49
Study 34246687 — intervention group
Group type: EXPERIMENTAL
Intervention: Transmuscular QL block with 20 mL 0.375% ropivacaine
Number of subjects: 80
Study 34246687 — intervention group
Group type: COMPARATOR
Intervention: TAP block with 20 mL 0.375% ropivacaine
Number of subjects: 80
Study 34246687 — intervention group
Group type: EXPERIMENTAL
Intervention: Transmuscular QL block
Number of subjects: 80
Study 34246687 — intervention group
Group type: COMPARATOR
Intervention: TAP block
Number of subjects: 80
Study 35747231 — intervention group
Group type: EXPERIMENTAL
Intervention: Early management (within 1 month)
Number of subjects: 200
Study 35747231 — intervention group
Group type: COMPARATOR
Intervention: Usual care (∼6 months)
Number of subjects: 200
Study 35417636 — intervention group
Group type: COMPARATOR
Intervention: Nonoperative treatment
Number of subjects: 526
Study 35417636 — intervention group
Group type: EXPERIMENTAL
Intervention: Open repair
Number of subjects: 526
Study 35417636 — intervention group
Group type: EXPERIMENTAL
Intervention: Minimally invasive surgery
Number of subjects: 526
Study 33980526 — intervention group
Group type: EXPERIMENTAL
Intervention: Early calorie-protein restriction (6 kcal/kg/day, 0.2-0.4 g/kg/day)
Number of subjects: 3044
Study 33980526 — intervention group
Group type: COMPARATOR
Intervention: Standard calorie-protein targets (25 kcal/kg/day, 1.0-1.3 g/kg/day)
Number of subjects: 3044
Study 33475577 — intervention group
Group type: EXPERIMENTAL
Intervention: Extraoral approach (Group A)
Number of subjects: 100
Study 33475577 — intervention group
Group type: COMPARATOR
Intervention: Intraoral approach (Group B)
Number of subjects: 100
Study 88026749 — intervention group
Group type: EXPERIMENTAL
Intervention: HBV vaccination
Number of subjects: 600000
Study 88026749 — intervention group
Group type: COMPARATOR
Intervention: No HBV vaccination (Control)
Number of subjects: 600000
Study 35927162 — intervention group
Group type: EXPERIMENTAL
Intervention: Real tDCS
Number of subjects: 79
Study 35927162 — intervention group
Group type: COMPARATOR
Intervention: Sham tDCS
Number of subjects: 79
Study 33929805 — intervention group
Group type: EXPERIMENTAL
Intervention: Keratoconus (KC) prevalence screening
Number of subjects: 585
Study 36158129 — intervention group
Group type: EXPERIMENTAL
Intervention: Serum pepsinogen I (PGI) and pepsinogen II (PGII) levels in Hp-infected gastric cancer patients
Number of subjects: 100
Study 36158129 — intervention group
Group type: EXPERIMENTAL
Intervention: Serum TNF-α, IL-6, and IL-18 levels in Hp-infected gastric cancer patients
Number of subjects: 100
Study 36158129 — intervention group
Group type: EXPERIMENTAL
Intervention: Multivariate logistic regression analysis of independent risk factors for gastric cancer
Number of subjects: 100
Study 34041932 — intervention group
Group type: EXPERIMENTAL
Intervention: Experimental vaccine (details not specified)
Number of subjects: 0
Study 34041932 — intervention group
Group type: COMPARATOR
Intervention: Active comparator vaccine with established efficacy of 50%-70%
Number of subjects: 0
Study 34041932 — intervention group
Group type: COMPARATOR
Intervention: Active comparator vaccine with established efficacy of 90%-95%
Number of subjects: 0
Study 33334479 — intervention group
Group type: EXPERIMENTAL
Intervention: VR-based safety training
Number of subjects: 119
Study 33334479 — intervention group
Group type: COMPARATOR
Intervention: HFST training
Number of subjects: 119
Study 35100468 — intervention group
Group type: EXPERIMENTAL
Intervention: Alb‐NC (cerium oxide nanoparticles conjugated with albumin; 50 µg/ml)
Number of subjects: 9
Study 35100468 — intervention group
Group type: COMPARATOR
Intervention: Control (untreated grafts)
Number of subjects: 9
Study 32021148 — intervention group
Group type: EXPERIMENTAL
Intervention: Glycopyrrolate/formoterol fumarate metered dose inhaler (GFF MDI) 18/9.6 µg
Number of subjects: 729
Study 32021148 — intervention group
Group type: COMPARATOR
Intervention: Glycopyrrolate (GP) MDI 18 µg
Number of subjects: 729
Study 32021148 — intervention group
Group type: COMPARATOR
Intervention: Formoterol fumarate (FF) MDI 9.6 µg
Number of subjects: 729
Study 32021148 — intervention group
Group type: COMPARATOR
Intervention: Placebo MDI
Number of subjects: 729
Study 35294962 — intervention group
Group type: EXPERIMENTAL
Intervention: Cocoa extract supplement (500 mg flavanols/d, including 80 mg (‐)‐epicatechin)
Number of subjects: 21442
Study 35294962 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 21442
Study 35294962 — intervention group
Group type: EXPERIMENTAL
Intervention: Cocoa extract supplement
Number of subjects: 21442
Study 33340120 — intervention group
Group type: EXPERIMENTAL
Intervention: mexiletine 300 or 600 mg daily for 4 weeks
Number of subjects: 20
Study 33340120 — intervention group
Group type: COMPARATOR
Intervention: placebo
Number of subjects: 20
Study 36204512 — intervention group
Group type: EXPERIMENTAL
Intervention: Targeted care plus exercise intervention
Number of subjects: 96
Study 36204512 — intervention group
Group type: COMPARATOR
Intervention: Routine nursing (control group)
Number of subjects: 96
Study 32468131 — intervention group
Group type: EXPERIMENTAL
Intervention: Home-based exercise using a DVD
Number of subjects: 237
Study 32762718 — intervention group
Group type: EXPERIMENTAL
Intervention: Fire needle plus cupping (FC)
Number of subjects: 105
Study 32762718 — intervention group
Group type: COMPARATOR
Intervention: Famciclovir plus gabapentin (FG)
Number of subjects: 105
Study 32762718 — intervention group
Group type: COMPARATOR
Intervention: Fire needle plus cupping plus famciclovir (FCF)
Number of subjects: 105
Study 36858705 — intervention group
Group type: EXPERIMENTAL
Intervention: MPCs (mesenchymal precursor cells)
Number of subjects: 565
Study 36858705 — intervention group
Group type: COMPARATOR
Intervention: Sham-control
Number of subjects: 565
Study 32779246 — intervention group
Group type: EXPERIMENTAL
Intervention: iMBGrp3
Number of subjects: 387
Study 32779246 — intervention group
Group type: EXPERIMENTAL
Intervention: iMBSHH
Number of subjects: 387
Study 32779246 — intervention group
Group type: EXPERIMENTAL
Intervention: Subtype II
Number of subjects: 387
Study 32779246 — intervention group
Group type: EXPERIMENTAL
Intervention: Subtype VII and IV
Number of subjects: 387
Study 32779246 — intervention group
Group type: EXPERIMENTAL
Intervention: iMBSHH-II
Number of subjects: 387
Study 32779246 — intervention group
Group type: EXPERIMENTAL
Intervention: iMBSHH-I and iMBSHH-II
Number of subjects: 387
Study 33409020 — intervention group
Group type: EXPERIMENTAL
Intervention: Increasing fluid therapy before surgery
Number of subjects: 60
Study 33409020 — intervention group
Group type: COMPARATOR
Intervention: Standard care (control group)
Number of subjects: 60
Study 33294988 — intervention group
Group type: EXPERIMENTAL
Intervention: Shade coffee farms with larger, older trees
Number of subjects: 33
Study 33294988 — intervention group
Group type: EXPERIMENTAL
Intervention: Climate changes
Number of subjects: 33
Study 33294988 — intervention group
Group type: EXPERIMENTAL
Intervention: Bryophyte cover
Number of subjects: 33
Study 33294988 — intervention group
Group type: EXPERIMENTAL
Intervention: Tree size and diversity
Number of subjects: 33
Study 33294988 — intervention group
Group type: EXPERIMENTAL
Intervention: Agroforests
Number of subjects: 33
Study 32105616 — intervention group
Group type: EXPERIMENTAL
Intervention: Costochondral graft (CCG)
Number of subjects: 24
Study 32105616 — intervention group
Group type: EXPERIMENTAL
Intervention: Transport disk distraction osteogenesis (TDDO)
Number of subjects: 24
Study 32105616 — intervention group
Group type: COMPARATOR
Intervention: Both CCG and TDDO
Number of subjects: 24
Study 34505919 — intervention group
Group type: EXPERIMENTAL
Intervention: Enriched meal with 20g powder (8.1g β-glucans) of oven-dried Pleurotus ostreatus
Number of subjects: 22
Study 34505919 — intervention group
Group type: COMPARATOR
Intervention: Control meal without enrichment
Number of subjects: 22
Study 33247534 — intervention group
Group type: EXPERIMENTAL
Intervention: Flexible cystoscopy (15.5 Fr)
Number of subjects: 41
Study 33247534 — intervention group
Group type: COMPARATOR
Intervention: Rigid cystoscopy (15.5 Fr)
Number of subjects: 41
Study 34183577 — intervention group
Group type: EXPERIMENTAL
Intervention: 4-week TEA treatment
Number of subjects: 30
Study 34183577 — intervention group
Group type: EXPERIMENTAL
Intervention: Acute TEA
Number of subjects: 30
Study 34183577 — intervention group
Group type: EXPERIMENTAL
Intervention: Acute and chronic TEA
Number of subjects: 30
Study 34183577 — intervention group
Group type: EXPERIMENTAL
Intervention: Chronic TEA
Number of subjects: 30
Study 34183577 — intervention group
Group type: EXPERIMENTAL
Intervention: TEA treatment
Number of subjects: 30
Study 32013700 — intervention group
Group type: EXPERIMENTAL
Intervention: Ascorbic acid (AA) 200 mg/kg divided over 24 hours
Number of subjects: 20
Study 32013700 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 20
Study 35752012 — intervention group
Group type: EXPERIMENTAL
Intervention: Experimental group performing safety behavior toward innocuous stimulus
Number of subjects: 68
Study 35752012 — intervention group
Group type: COMPARATOR
Intervention: Control group (no safety behavior)
Number of subjects: 68
Study 35752012 — intervention group
Group type: EXPERIMENTAL
Intervention: Experimental group performing safety behavior toward innocuous stimulus (Study 2)
Number of subjects: 68
Study 33596538 — intervention group
Group type: EXPERIMENTAL
Intervention: Virtual Reality Training (VRT)
Number of subjects: 54
Study 33596538 — intervention group
Group type: COMPARATOR
Intervention: Combined Physical Rehabilitation
Number of subjects: 54
Study 33596538 — intervention group
Group type: COMPARATOR
Intervention: Control
Number of subjects: 54
Study 33596538 — intervention group
Group type: EXPERIMENTAL
Intervention: All groups (including VRT, Combined Physical Rehabilitation, Control)
Number of subjects: 54
Study 33596538 — intervention group
Group type: EXPERIMENTAL
Intervention: VRT
Number of subjects: 54
Study 32451267 — intervention group
Group type: EXPERIMENTAL
Intervention: Acid etchant+Transbond XT™
Number of subjects: 48
Study 32451267 — intervention group
Group type: EXPERIMENTAL
Intervention: Vertise Flow™
Number of subjects: 48
Study 32451267 — intervention group
Group type: EXPERIMENTAL
Intervention: Acid etchant+Vertise Flow™
Number of subjects: 48
Study 32451267 — intervention group
Group type: EXPERIMENTAL
Intervention: Sandblasting (surface treatment)
Number of subjects: 48
Study 32451267 — intervention group
Group type: COMPARATOR
Intervention: No treatment (surface treatment)
Number of subjects: 48
Study 32451267 — intervention group
Group type: COMPARATOR
Intervention: Er:YAG laser (surface treatment)
Number of subjects: 48
Study 35178708 — intervention group
Group type: EXPERIMENTAL
Intervention: Systemic Family Therapy added to Treatment As Usual
Number of subjects: 60
Study 35178708 — intervention group
Group type: COMPARATOR
Intervention: Treatment As Usual alone
Number of subjects: 60
Study 34633405 — intervention group
Group type: EXPERIMENTAL
Intervention: Aspirin (81 mg orally once daily; n=164)
Number of subjects: 7000
Study 34633405 — intervention group
Group type: EXPERIMENTAL
Intervention: Prophylactic-dose apixaban (2.5 mg orally twice daily; n=165)
Number of subjects: 7000
Study 34633405 — intervention group
Group type: EXPERIMENTAL
Intervention: Therapeutic-dose apixaban (5 mg orally twice daily; n=164)
Number of subjects: 7000
Study 34633405 — intervention group
Group type: COMPARATOR
Intervention: Placebo (n=164)
Number of subjects: 7000
Study 34633405 — intervention group
Group type: EXPERIMENTAL
Intervention: Aspirin
Number of subjects: 7000
Study 34633405 — intervention group
Group type: EXPERIMENTAL
Intervention: Prophylactic-dose apixaban
Number of subjects: 7000
Study 34633405 — intervention group
Group type: EXPERIMENTAL
Intervention: Therapeutic-dose apixaban
Number of subjects: 7000
Study 32436135 — intervention group
Group type: EXPERIMENTAL
Intervention: Mud-bath therapy with sulfurous-arsenical-ferruginous mineral water
Number of subjects: 212
Study 32613672 — intervention group
Group type: EXPERIMENTAL
Intervention: Nucleos(t)ide analogues (NAs)
Number of subjects: 76
Study 34726324 — intervention group
Group type: EXPERIMENTAL
Intervention: Canagliflozin 100 mg daily
Number of subjects: 68
Study 34726324 — intervention group
Group type: COMPARATOR
Intervention: Metformin 1500 to 2000 mg daily
Number of subjects: 68
Study 32979577 — intervention group
Group type: EXPERIMENTAL
Intervention: valaciclovir treatment for 3 months
Number of subjects: 53
Study 32979577 — intervention group
Group type: EXPERIMENTAL
Intervention: Development of IgG anti-N-methyl-D-aspartate receptor (NMDAR) antibodies
Number of subjects: 53
Study 32979577 — intervention group
Group type: EXPERIMENTAL
Intervention: Previous development of IgG anti-NMDAR
Number of subjects: 53
Study 32979577 — intervention group
Group type: EXPERIMENTAL
Intervention: Age
Number of subjects: 53
Study 32979577 — intervention group
Group type: EXPERIMENTAL
Intervention: CSF NFL levels
Number of subjects: 53
Study 32652616 — intervention group
Group type: EXPERIMENTAL
Intervention: Cannabidiol (CBD; 20 mg/kg/day)
Number of subjects: 20
Study 32652616 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 20
Study 32652616 — intervention group
Group type: EXPERIMENTAL
Intervention: Cannabidiol (CBD; 20 mg/kg/day) with clobazam (CLB)
Number of subjects: 20
Study 36083324 — intervention group
Group type: EXPERIMENTAL
Intervention: High-volume injection (HVI) - 50 mL
Number of subjects: 62
Study 36083324 — intervention group
Group type: COMPARATOR
Intervention: Placebo injection - 2 mL (saline and lidocaine)
Number of subjects: 62
Study 36083324 — intervention group
Group type: EXPERIMENTAL
Intervention: High-volume injection (HVI)
Number of subjects: 62
Study 36083324 — intervention group
Group type: COMPARATOR
Intervention: Placebo injection
Number of subjects: 62
Study 33268417 — intervention group
Group type: EXPERIMENTAL
Intervention: Adolescent transition package (ATP) implemented in 10 HIV clinics, including provider tools for disclosure and transition, with training for healthcare providers and continuous quality improvement for 6 months, followed by 1 year of implementation.
Number of subjects: 200
Study 33268417 — intervention group
Group type: COMPARATOR
Intervention: Standard of care provided in 10 control clinics.
Number of subjects: 200
Study 33268417 — intervention group
Group type: EXPERIMENTAL
Intervention: Adolescent transition package (ATP) implemented in 10 HIV clinics.
Number of subjects: 200
Study 33487095 — intervention group
Group type: EXPERIMENTAL
Intervention: Electronic stimulation (ES) administered to bilateral lower legs using tapping mode (3 Hz)
Number of subjects: 46
Study 33487095 — intervention group
Group type: COMPARATOR
Intervention: Sham group (no active stimulation)
Number of subjects: 46
Study 33929040 — intervention group
Group type: EXPERIMENTAL
Intervention: Wagyu‐Cross meat
Number of subjects: 34
Study 33929040 — intervention group
Group type: COMPARATOR
Intervention: Commercial meat
Number of subjects: 34
Study 34890373 — intervention group
Group type: EXPERIMENTAL
Intervention: Darvadstrocel
Number of subjects: 40
Study 34890373 — intervention group
Group type: COMPARATOR
Intervention: Control (saline solution)
Number of subjects: 40
Study 34051006 — intervention group
Group type: EXPERIMENTAL
Intervention: 50 µl Receptal solution
Number of subjects: 96
Study 34051006 — intervention group
Group type: EXPERIMENTAL
Intervention: 100 µl Receptal solution
Number of subjects: 96
Study 34051006 — intervention group
Group type: EXPERIMENTAL
Intervention: 150 µl Receptal solution
Number of subjects: 96
Study 34051006 — intervention group
Group type: COMPARATOR
Intervention: Control group (no treatment)
Number of subjects: 96
Study 32601101 — intervention group
Group type: EXPERIMENTAL
Intervention: Colon capsule endoscopy (CCE) as a filter test prior to faecal immunochemical test (FIT)
Number of subjects: 124214
Study 32601101 — intervention group
Group type: COMPARATOR
Intervention: Standard screening procedures (Control group)
Number of subjects: 124214
Study 33895547 — intervention group
Group type: EXPERIMENTAL
Intervention: internet‐delivered cognitive behavioral treatment that included exposure (ICBT)
Number of subjects: 309
Study 33895547 — intervention group
Group type: COMPARATOR
Intervention: internet‐delivered cognitive behavioral treatment without exposure (ICBT‐WE)
Number of subjects: 309
Study 35696698 — intervention group
Group type: EXPERIMENTAL
Intervention: Duloxetine 60 mg capsules
Number of subjects: 60
Study 35696698 — intervention group
Group type: COMPARATOR
Intervention: Placebo capsules (Becosules)
Number of subjects: 60
Study 33497135 — intervention group
Group type: EXPERIMENTAL
Intervention: Vitamin D3
Number of subjects: 0
Study 33497135 — intervention group
Group type: EXPERIMENTAL
Intervention: Omega-3 fatty acids
Number of subjects: 0
Study 33497135 — intervention group
Group type: EXPERIMENTAL
Intervention: Strength training exercise program
Number of subjects: 0